Loading clinical trials...
Loading clinical trials...
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial
Conditions
Interventions
Camrelizumab
Apatinib
+2 more
Locations
1
China
Shanghai Ninth People's Hospital
Shanghai, Shanghai Municipality, China
Start Date
April 23, 2020
Primary Completion Date
November 2, 2020
Completion Date
November 10, 2023
Last Updated
November 22, 2023
NCT05030597
NCT06321003
NCT06673329
NCT04191460
NCT05980702
NCT03385720
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions